{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T01:20:26Z","timestamp":1783473626612,"version":"3.55.0"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To comparatively evaluate the efficacy and safety of the two aripiprazole long-acting injectable (LAI) initiation regimens, including one-injection start (OIS) regimen and two-injection start (TIS) regimen, in patients with bipolar disorder (BD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 46 BD patients experiencing acute manic episodes with psychotic or mixed features were included in this observational study. Patients were divided into two groups based on the aripiprazole LAI initiation regimen including OIS group (n=23; patients received a single 400 mg LAI injection on Day 1, followed by oral aripiprazole (15\u201320 mg\/day) for 14 days) and TIS group (n=23; patients received two 400 mg doses of aripiprazole LAI administered on the same day together with a single 20 mg oral dose of aripiprazole). Data on patient demographics, clinical characteristics and previous hospitalization were retrieved from hospital records. The effectiveness of the treatment was evaluated based on the Young Mania Rating Scale (YMRS) and Hamilton Depression Scale (HAM-D) scores recorded on Day 1 and Day 15 of the injection. The safety and tolerability of the OIS and TIS regimens were assessed via Udvalg for Kliniske Unders\u00f8gelser Side Effect Rating Scale (UKU-SERS) scores recorded on Day 15 of the injection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At baseline, the rate of previous hospitalization was higher in the OIS group than in the TIS group (60.9% vs. 26.1%, p=0.037). YMRS scores on Day 15 (11.0 \u00b1 5.7 vs. 16.6 \u00b1 6.2, p=0.003) and UKU-SERS Psychiatric adverse effects score on Day 15 (4.4 \u00b1 1.8 vs. 7.5 \u00b1 3.2, p&amp;lt;0.001) were significantly lower in the TIS group than in the OIS group. YMRS scores and HAM-D scores were significantly decreased from Day 1 to Day 15 of injection in both TIS (p= 0.002 and p=0.025, respectively) and OIS (p= 0.002 and p=0.025, respectively) groups, while the change was significantly higher in the TIS group. Linear regression analysis revealed that OIS regimen was a significant risk factor for increase in YMRS Day 15 scores (B: 0.434, p=0.003) and increase in UKU-SERS psychiatric scores (B: 0.526, p&amp;lt;0.001). Logistic regression analysis revealed that OIS regimen was an independent determinant of previous hospitalization history (OR: 4.407, p=0.020), increasing the likelihood of previous hospitalization by 4.407 times compared to TIS regimen. Both regimens had tolerable side effects, with no life-threatening issues.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study highlights the efficacy and reliability of the TIS regimen in treating BD episodes, potentially facilitating faster clinical recovery by reducing the need for prolonged oral supplementation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpsyt.2025.1627052","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T12:52:12Z","timestamp":1769172732000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Two-injection start regimen of long-acting aripiprazole for bipolar disorder: tips and tricks for better efficacy and tolerability"],"prefix":"10.3389","volume":"16","author":[{"given":"Gulcin","family":"Elboga","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Gaziantep University Faculty of Medicine","place":["Gaziantep, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irem","family":"Surme","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Kayseri State Hospital","place":["Kayseri, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammet","family":"Sancaktar","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Gaziantep University Faculty of Medicine","place":["Gaziantep, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahad\u0131r","family":"Demir","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Gaziantep University Faculty of Medicine","place":["Gaziantep, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sengul Kocamer","family":"Sahin","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Health Sciences Training and Research Hospital","place":["Adana, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdurrahman","family":"Altindag","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Gaziantep University Faculty of Medicine","place":["Gaziantep, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18863\/pgy.534574","article-title":"Contribution of skills training in a community mental health center to daily living activities and cognitive functions","volume":"11","author":"Elboga","year":"2019","journal-title":"Curr Approaches Psychiatry"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00241-X","article-title":"Bipolar disorder","volume":"387","author":"Grande","year":"2016","journal-title":"Lancet (London England)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.17826\/cumj.461779","article-title":"Quality of life, adherence to medical treatment, insight, and functionality of patients benefiting from community mental health center","volume":"44","author":"\u015eahin","year":"2019","journal-title":"Cukurova Med J"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.v61n0802","article-title":"Clinical factors associated with treatment noncompliance in euthymic bipolar patients","volume":"61","author":"Colom","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/NMD.0000000000001151","article-title":"Illness insight and medication adherence among patients with bipolar disorder","volume":"208","author":"Guti\u00e9rrez-Rojas","year":"2020","journal-title":"J Nervous Ment Dis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1177\/2045125318804364","article-title":"Medication nonadherence in bipolar disorder: a narrative review","volume":"8","author":"Jawad","year":"2018","journal-title":"Ther Adv Psychopharmacol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1177\/20451253231163682","article-title":"Long-acting injecta ble antipsychotics for the treatment of bipolar disorder: evidence from mirror-image studies","volume":"13","author":"Bartoli","year":"2023","journal-title":"Ther Adv Psychopharmacol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2019.02.003","article-title":"Long-acting injectab le antipsychotics (LAIs) for maintenance treatment of bipolar and schizoaffective disorders: A systematic review","volume":"29","author":"Pacchiarotti","year":"2019","journal-title":"Eur neuropsychopharmacology: J Eur Coll Neuropsychopharmacol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2165\/11631310-000000000-00000","article-title":"Long-acting injecta ble antipsychotics for the maintenance treatment of bipolar disorder","volume":"26","author":"Gigante","year":"2012","journal-title":"CNS Drugs"},{"key":"B10","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/bdi.12609","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder","volume":"20","author":"Yatham","year":"2018","journal-title":"Bipolar Disord"},{"key":"B11","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1111\/bdi.13035","article-title":"The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders: Major depression summary","volume":"22","author":"Malhi","year":"2020","journal-title":"Bipolar Disord"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0231-7","article-title":"Aripiprazole (ABILIFY MAINTENA\u00ae): a review of its use as maintenance treatment for adult patients with schizophrenia","volume":"74","author":"Shirley","year":"2014","journal-title":"Drugs"},{"key":"B13","doi-asserted-by":"crossref","DOI":"10.1002\/9781119870203","volume-title":"The Maudsley prescribing guidelines in psychiatry","author":"Taylor","year":"2021"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-025-03130-w","article-title":"Survey on the initiation of aripiprazole once-monthly via a two-injection start in adult patients with schizophrenia: experience of european healthcare professionals","volume":"42","author":"Fagiolini","year":"2025","journal-title":"Adv Ther"},{"key":"B15","unstructured":"Aripiprazole european medicines agency prescribing information\n          \n          2017"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2021.1965974","article-title":"An alternative start regimen with aripiprazole once-monthly in patients with schizophrenia: population pharmacokinetic analysis of a single-day, two-injection start with gluteal and\/or deltoid intramuscular injection","volume":"37","author":"Wang","year":"2021","journal-title":"Curr Med Res Opin"},{"key":"B17","doi-asserted-by":"publisher","first-page":"954","DOI":"10.3390\/jcm14030954","article-title":"Efficacy and safety of adjunctive aripiprazole LAI or paliperidone LAI for the management of patients suffering from bipolar I disorder with comorbid obsessive-compulsive disorder","volume":"14","author":"Martiadis","year":"2025","journal-title":"J Clin Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.133.5.429","article-title":"A rating scale for mania: reliability, validity and sensitivity","volume":"133","author":"Young","year":"1978","journal-title":"Br J Psychiatry"},{"key":"B19","article-title":"Young mani derecelendirme \u00f6l\u00e7e\u011finin T\u00fcrkiye\u2019de ge\u00e7erlik ve g\u00fcvenilirli\u011fi","volume":"13","author":"Karada\u011f","year":"2001","journal-title":"T\u00fcrk Psikiyatri Dergisi"},{"key":"B20","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"J neurology neurosurgery Psychiatry"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1053\/comp.2001.19756","article-title":"Reliability and validity of the Turkish version of the Hamilton Depression Rating Scale","volume":"42","author":"Akdemir","year":"2001","journal-title":"Compr Psychiatry"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1987.tb10566.x","article-title":"The UKU side effect rating scale: a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients","volume":"76","author":"Lingjaerde","year":"1987","journal-title":"Acta Psychiatrica Scandinavica."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2","DOI":"10.5455\/NYS.20200813075946","article-title":"Turkish validity reliability of udvalg for kliniske unders\u00f8gelser side effect rating scale in patients with chronic schizophrenia","volume":"58","author":"Erdo\u011fan","year":"2020","journal-title":"Neuropsychiatr Invest"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.2307\/2987742","article-title":"Measuring skewness and kurtosis","volume":"33","author":"Groeneveld","year":"1984","journal-title":"Statistician"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1177\/0013164490504001","article-title":"Tests for normality and measures of skewness and kurtosis: their place in research reporting","volume":"50","author":"Hopkins","year":"1990","journal-title":"Educ psychol Measurement"},{"key":"B26","doi-asserted-by":"publisher","first-page":"64","DOI":"10.5505\/kpd.2020.49369","article-title":"The effects of the frequency of participation to the community mental health center on insight, treatment adherence and functionality","volume":"23","author":"Sahin","year":"2020","journal-title":"Turkish J Clin Psychiatry"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000001629","article-title":"Two-injection start regimen of long-acting aripiprazole in 133 patients with schizophrenia","volume":"43","author":"Cuomo","year":"2023","journal-title":"J Clin Psychopharmacol"},{"key":"B28","first-page":"1","article-title":"Exploring the efficacy and tolerability of two-injection start regimen of long-acting aripiprazole: A descriptive case series analysis","volume-title":"Neuropsychopharmacology Reports","author":"Sungur","year":"2024"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2025.1627052\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T12:52:13Z","timestamp":1769172733000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2025.1627052\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":28,"alternative-id":["10.3389\/fpsyt.2025.1627052"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2025.1627052","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]},"article-number":"1627052"}}